PACB Valuation

Pacific Biosciences of California Inc

Add to Watchlist

Advanced Chart

1.280

+0.05(4.065%)1D

Overview
Forecast
Valuation
Earnings

PACB Relative Valuation

PACB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PACB is overvalued; if below, it's undervalued.

Historical Valuation

Pacific Biosciences of California Inc (PACB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.17 is considered Undervalued compared with the five-year average of -0.69. The fair price of Pacific Biosciences of California Inc (PACB) is between 16.38 to 29.54 according to relative valuation methord. Compared to the current price of 1.23 USD , Pacific Biosciences of California Inc is Undervalued By 92.49%.

Relative Value

Fair Zone

16.38-29.54

Current Price：1.23

92.49%

Undervalued

-2.11

Trailing

Forward

-5.17

EV/EBITDA

Pacific Biosciences of California Inc. (PACB) has a current EV/EBITDA of -5.17. The 5-year average EV/EBITDA is -13.41. The thresholds are as follows: Strongly Undervalued below -38.55, Undervalued between -38.55 and -25.98, Fairly Valued between -0.84 and -25.98, Overvalued between -0.84 and 11.74, and Strongly Overvalued above 11.74. The current Forward EV/EBITDA of -5.17 falls within the Historic Trend Line -Fairly Valued range.

-4.31

EV/EBIT

Pacific Biosciences of California Inc. (PACB) has a current EV/EBIT of -4.31. The 5-year average EV/EBIT is -12.02. The thresholds are as follows: Strongly Undervalued below -34.37, Undervalued between -34.37 and -23.20, Fairly Valued between -0.85 and -23.20, Overvalued between -0.85 and 10.32, and Strongly Overvalued above 10.32. The current Forward EV/EBIT of -4.31 falls within the Historic Trend Line -Fairly Valued range.

2.17

Pacific Biosciences of California Inc. (PACB) has a current PS of 2.17. The 5-year average PS is 15.82. The thresholds are as follows: Strongly Undervalued below -13.19, Undervalued between -13.19 and 1.32, Fairly Valued between 30.33 and 1.32, Overvalued between 30.33 and 44.84, and Strongly Overvalued above 44.84. The current Forward PS of 2.17 falls within the Historic Trend Line -Fairly Valued range.

-4.51

P/OCF

Pacific Biosciences of California Inc. (PACB) has a current P/OCF of -4.51. The 5-year average P/OCF is -16.46. The thresholds are as follows: Strongly Undervalued below -71.93, Undervalued between -71.93 and -44.19, Fairly Valued between 11.28 and -44.19, Overvalued between 11.28 and 39.01, and Strongly Overvalued above 39.01. The current Forward P/OCF of -4.51 falls within the Historic Trend Line -Fairly Valued range.

-3.14

P/FCF

Pacific Biosciences of California Inc. (PACB) has a current P/FCF of -3.14. The 5-year average P/FCF is -18.90. The thresholds are as follows: Strongly Undervalued below -108.33, Undervalued between -108.33 and -63.61, Fairly Valued between 25.82 and -63.61, Overvalued between 25.82 and 70.53, and Strongly Overvalued above 70.53. The current Forward P/FCF of -3.14 falls within the Historic Trend Line -Fairly Valued range.

Pacific Biosciences of California Inc (PACB) has a current Price-to-Book (P/B) ratio of 6.01. Compared to its 3-year average P/B ratio of 2.78 , the current P/B ratio is approximately 116.17% higher. Relative to its 5-year average P/B ratio of 6.91, the current P/B ratio is about -13.02% higher. Pacific Biosciences of California Inc (PACB) has a Forward Free Cash Flow (FCF) yield of approximately -41.23%. Compared to its 3-year average FCF yield of -29.43%, the current FCF yield is approximately 40.09% lower. Relative to its 5-year average FCF yield of -19.48% , the current FCF yield is about 111.60% lower.

6.01

P/B

Median3y

2.78

Median5y

6.91

-41.23

FCF Yield

Median3y

-29.43

Median5y

-19.48

Competitors Valuation Multiple

The average P/S ratio for PACB's competitors is 121.01, providing a benchmark for relative valuation. Pacific Biosciences of California Inc Corp (PACB) exhibits a P/S ratio of 2.17, which is -98.21% above the industry average. Given its robust revenue growth of 10.42%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PACB.O

Pacific Biosciences of California Inc

Mesa Laboratories Inc

Alpha Tau Medical Ltd

Performance Decomposition

Market capitalization of PACB decreased by 27.65% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.48 to -0.67.

The secondary factor is the Revenue Growth, contributed 10.42%to the performance.

Overall, the performance of PACB in the past 1 year is driven by P/E Change. Which is more unsustainable.

10.42%

36.01M → 39.77M

Revenue Growth

-78.09%

-481.27 → -105.44

Margin Expansion

40.02%

-0.48 → -0.67

P/E Change

-27.65%